File
Pursuant to Rule 424(b)(5)
Registration
No. 333-282840
PROSPECTUS
MicroVision,
Inc.
Up
to 42,692,019 Shares of Common Stock
High
Trail Special Situations, LLC, or the Selling Stockholder, and any additional selling stockholders who may be identified in one or more
prospectus supplements, may sell from time to time up to 42,692,019 shares of our common stock, or the Shares, in one or more
transactions.
The
42,692,019 shares offered hereby are issuable upon the potential conversion of the senior secured convertible note in the aggregate principal amount of $45,000,000, or the
Convertible Note, sold by us pursuant to the Securities Purchase Agreement dated October 14, 2024, in a private placement that we
consummated on October 23, 2024, or the Private Placement.
The
registration of these Shares does not necessarily mean that any holder will sell any of its Shares or that the Convertible Note will
be converted into shares of common stock. We are not offering for sale any shares of our common stock pursuant to this prospectus and
we will not receive any proceeds from the resale of the shares of our common stock offered hereby. We have agreed to pay certain expenses
in connection with this registration statement.
The
Selling Stockholder may offer the Shares from time to time as it may determine, through public or private transactions or through other
means, as described in the section entitled “Plan of Distribution” or a supplement to this prospectus. The Selling Stockholder
may offer all or part of the Shares registered hereby for resale from time to time directly to purchasers, through agents selected by
the Selling Stockholder, or to or through underwriters or dealers, at either prevailing market prices or at privately negotiated prices.
If agents, underwriters or dealers are used in the sale of the Shares by the Selling Stockholder, such agents, underwriters or dealers
will be named and their compensation described in any applicable prospectus supplement. The Selling Stockholder may also sell the Shares
under Rule 144 under the Securities Act of 1933, as amended, if available, rather than under this prospectus.
We
may amend or supplement this prospectus from time to time by filing amendments or supplements as required. You should carefully read
this prospectus and any amendments or supplements, together with the additional information described under the heading “Where
You Can Find More Information,” before you invest.
Our
common stock is traded on The Nasdaq Global Market under the symbol “MVIS.” On November 12, 2024, the closing price
of our common stock on The Nasdaq Global Market was $0.99 per share.
The
securities offered in this prospectus involve a high degree of risk. You should carefully consider the information under the heading
“Risk Factors” set forth herein on page 6 and in our filings made with the Securities and Exchange
Commission, which are incorporated by reference in this prospectus, in determining whether to purchase our
securities.
Our
executive offices are located at 18390 NE 68th Street, Redmond, Washington 98052, and our telephone number is (425) 936-6847.
Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.
The
date of this prospectus is November 27, 2024.
TABLE
OF CONTENTS
ABOUT
THIS PROSPECTUS
This
prospectus is part of a shelf registration statement that we filed with the Securities and Exchange Commission, or the SEC. Pursuant
to this prospectus, the Selling Stockholder may, from time to time, sell the Shares described in this prospectus in one or more offerings
if, and to the extent, the Selling Stockholder converts the Convertible Note for shares of our common stock.
A
prospectus supplement and, if necessary, a free writing prospectus, may also add to, update or change information contained in this prospectus.
Accordingly, to the extent inconsistent, the information in this prospectus, including the information incorporated by reference into
this prospectus, will be deemed to be modified or superseded by any inconsistent information contained in a prospectus supplement or
a free writing prospectus. You should read carefully this prospectus, any applicable prospectus supplement and any free writing prospectus,
together with the additional information incorporated by reference in this prospectus described below under “Where You Can Find
More Information” before making an investment in our securities.
We
have not authorized anyone to give you any additional information different from that contained in this prospectus, any accompanying
prospectus supplement or any free writing prospectus provided in connection with an offering. We take no responsibility for, and can
provide no assurance as to the reliability of, any other information that others may give you.
You
should assume that the information appearing in this prospectus, any prospectus supplement, the documents incorporated by reference and
any related free writing prospectus is accurate only as of their respective dates. Our business, financial condition, results of operations
and prospects may have changed since that date.
This
prospectus is not an offer to sell or solicitation of an offer to buy our securities in any circumstances under which or jurisdiction
in which the offer or solicitation is unlawful. Unless the context otherwise indicates, the terms “MicroVision,” “Company,”
“we,” “us,” and “our” as used in this prospectus refer to MicroVision, Inc. and its consolidated
subsidiaries. The phrase “this prospectus” refers to this prospectus and any applicable prospectus supplement, unless the
context otherwise requires.
NOTE
REGARDING FORWARD-LOOKING STATEMENTS
This
prospectus and the documents incorporated by reference in this prospectus contain forward-looking statements, within the meaning of Section
27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended,
or the Exchange Act, and is subject to the safe harbor created by those sections. Such statements may include, but are not limited to,
projections of revenues, income or loss, capital expenditures, plans for product development and cooperative arrangements, future operations,
financing needs or plans of MicroVision, as well as assumptions relating to the foregoing. The words “anticipate,” “believe,”
“estimate,” “expect,” “goal,” “may,” “plan,” “project,” “will,”
and similar expressions identify forward-looking statements, which speak only as of the date the statement was made.
These
forward-looking statements are not guarantees of future performance. Factors that could cause actual results to differ materially from
those projected in such forward-looking statements include our ability to operate with limited cash or to raise additional capital when
needed; risks relating to the Convertible Note; market acceptance of our technologies and products or for products incorporating our
technologies; the failure of our commercial partners to perform as expected under our agreements; our financial and technical resources
relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies;
our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract
awards and develop partnership opportunities; the timing of commercial product launches and delays in product development; the ability
to achieve key technical milestones in key products; dependence on third parties to develop, manufacture, sell and market our products;
potential product liability claims; our ability to maintain our listing on The Nasdaq Stock Market; and other risk factors identified
from time to time in this prospectus (including any prospectus supplement) and our SEC reports, including the our Annual Report on Form
10-K filed with the SEC. These factors are not intended to represent a complete list of the general or specific factors that may affect
us. It should be recognized that other factors, including general economic factors and business strategies, may be significant, now or
in the future, and the factors set forth in this prospectus may affect us to a greater extent than indicated. Except as expressly required
by federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result
of new information, future events, changes in circumstances or any other reason.
SUMMARY
The
following summary is qualified in its entirety by, and should be read together with, our consolidated financial statements and related
notes thereto and the more detailed information appearing elsewhere or incorporated by reference in this prospectus. Before you decide
to invest in our common stock, you should read the entire prospectus carefully, including the risk factors and the financial statements
and related notes included or incorporated by reference in this prospectus.
Our
Company
Overview
MicroVision
is a global developer and supplier of lidar hardware and software solutions focused primarily on automotive lidar and advanced driver-assistance
systems, or ADAS, markets where we can deliver safe mobility at the speed of life. We offer a suite of light detection and ranging, or
lidar, sensors and perception and validation software to automotive original equipment manufacturers, or OEMs, for ADAS and autonomous
vehicle, or AV, applications, as well as to complementary markets for non-automotive applications including industrial, robotics and
smart infrastructure. Our long history of developing and commercializing the core components of our lidar hardware and related software,
combined with the experience of the team we acquired from Ibeo Automotive Systems, or Ibeo, with automotive-grade qualification, gives
us a compelling advantage as a development and commercial partner.
Founded
in 1993, MicroVision, Inc. is a pioneer in laser beam scanning, or LBS, technology, which is based on our patented expertise in micro-electromechanical
systems, or MEMS, laser diodes, opto-mechanics, electronics, algorithms and software and how those elements are packaged into a small
form factor. Throughout our history, we have combined our proprietary technology with our development expertise to create innovative
solutions to address existing and emerging market needs, such as augmented reality microdisplay engines; interactive display modules;
consumer lidar components; and, most recently, automotive lidar sensors and software solutions for the automotive market.
In
January 2023, we acquired certain strategic assets of Germany-based Ibeo, which was founded in 1998 as a lidar hardware and software
provider. Ibeo developed and launched the first lidar sensor to be automotive qualified for serial production with a Tier 1 automotive
supplier and that is currently available in passenger cars by premium OEMs. Ibeo developed software solutions, including perception and
validation software, which are also used by premium OEMs. In addition, Ibeo sold its products for non-automotive uses such as industrial,
smart infrastructure and robotics applications.
For
the automotive market, our integrated solution combines our MEMS-based dynamic-range lidar sensor and perception software, to be integrated
on our custom application specific integrated circuit, or ASIC, targeted for sale to premium automotive OEMs and Tier 1 automotive suppliers.
Our ADAS solution is intended to leverage edge computing and custom ASICs to enable our hardware and perception software to be integrated
into an OEM’s ADAS stack.
In
addition to our dynamic-range and long-range MAVIN sensor and perception software solution for the automotive market, our product suite
includes our short-range flash-based MOVIA lidar sensor, for automotive and industrial applications, including smart infrastructure,
robotics, and other commercial segments. Also, our validation software tool, the MOSAIK suite, is used by OEMs and other customers including
Tier 1s for validating vehicle sensors for ADAS and AV applications. The tool includes software that automates the manual data classification
or annotation process, significantly reducing the time and resources required by OEMs to validate their ADAS and AV systems.
In
the recent past, we developed micro-display concepts and designs for use in head-mounted augmented reality, or AR, headsets and developed
a 1440i MEMS module supporting AR headsets. We also developed an interactive display solution targeted at the smart speakers market and
a small consumer lidar sensor for use indoors with smart home systems.
To
date, we have been unable to secure the customers at the scale needed to successfully launch our products. We have incurred substantial
losses since inception, incurred a significant loss during the fiscal year ended December 31, 2023 and expect to incur a significant
loss during the fiscal year ended December 31, 2024.
Corporate
Information
We
were founded in 1993 as a Washington corporation and reincorporated in 2003 under the laws of the State of Delaware. Our principal office
is located at 18390 NE 68th Street, Redmond, WA 98052 and our telephone number is 425-936-6847. We maintain a website at www.microvision.com,
where general information about us is available. We do not incorporate the information on our website into this prospectus supplement
or the accompanying prospectus and you should not consider it part of this prospectus supplement or the accompanying prospectus.
Convertible
Note
On
October 14, 2024, we entered into a Securities Purchase Agreement, or the Purchase Agreement, pursuant to which we agreed to sell and
issue to the Selling Stockholder senior secured convertible notes in the aggregate principal amount of up to $75,000,000. On October
23, 2024, we issued the Convertible Note to the Selling Stockholder in the aggregate principal amount of $45,000,000, or the Principal
Amount. Upon satisfaction of additional conditions set forth in the Purchase Agreement, we may issue additional senior secured convertible
notes to the Selling Stockholder in the aggregate principal amount of up to $30,000,000 at subsequent closings. The shares of common
stock underlying any subsequently issued senior secured convertible notes will be registered in a future registration statement.
The Convertible Note bears zero coupon and matures on October 1, 2026. The Convertible Note ranks senior to all of our outstanding and
future indebtedness, and is secured by a first priority perfected security interest in all of our bank and securities accounts, now owned
and hereafter created or acquired.
The
Selling Stockholder will have the option to partially redeem (i) up to $1,925,000 on the first day of each month beginning on and
including January 1, 2025 and ending on and including March 1, 2025 and (ii) up to $3,850,000 on the first day of each
month beginning on and including April 1, 2025 and ending on and including October 1, 2026.
The
Convertible Note will be optionally convertible by the Selling Stockholder, subject to certain limitations as described below. If the
Selling Stockholder elects to convert the Convertible Note with respect to the Initial Principal Amount, which is a portion of the Principal
Amount equal to $12,250,000, the conversion price for such Initial Principal Amount will be an amount equal to (i) $1,000 divided
by (ii) the “First Conversion Rate,” which is an amount equal to one hundred ten percent (110%) of a fraction whose numerator
is $1,000 and whose denominator is the lesser of (A) $1.5960 and (B) ninety percent (90%) of the Nasdaq Minimum Price (as defined in
Nasdaq Rule 5635(d)) as of the effective date of this registration statement, subject to customary anti-dilution adjustments. If the
Selling Stockholder elects to convert the Convertible Note with respect to any Principal Amount not constituting the Initial Principal
Amount, the conversion price will be an amount equal to (i) $1,000 divided by (ii) the “Second Conversion Rate,” which is
an amount equal to 626.5664 shares of common stock per $1,000 Principal Amount.
If
the issuance of Shares requires approval by our stockholders to satisfy Nasdaq Listing Rule 5635(d)(2), until the requisite stockholder
approval is obtained, in no event will the number of shares of our common stock issuable upon conversion or otherwise pursuant to the
Convertible Note exceed 42,692,019 shares in the aggregate. We do not expect such stockholder approval to be required in connection
with the issuance of the Shares. The number of shares registered hereby represents the maximum amount of shares that could be issued
pursuant to the Convertible Note absent stockholder approval. If we elect to issue additional senior secured convertible notes pursuant
to the Purchase Agreement, stockholder approval may be required.
The
conversion of the Convertible Note is subject to certain conditions, including that the Selling Stockholder remains within the Beneficial
Ownership Limitation (as defined below).
Subject
to certain conditions, we can require the Selling Stockholder to convert the Convertible Note, or a Forced Conversion, at any time if,
for the immediately preceding 20 consecutive trading days, the stock price has closed at or above $2.3940. The conversion rate for a
Forced Conversion will be the same as the conversion price which would then be applicable for an optional conversion by the Selling Stockholder
described above.
The
Convertible Note may not be converted into shares of our common stock if such conversion would result in the Selling Stockholder and
its affiliates beneficially owning an aggregate of in excess of 4.99% of the then-outstanding shares of our common stock, provided that
such ownership limitation may be (i) increased by the Selling Stockholder to no greater than 9.99% upon 61 days’ notice
and (ii) decreased immediately by the Selling Stockholder upon notice (such limitation is referred to as the Beneficial Ownership
Limitation).
The
Convertible Note provides for certain events of default, such as our failure to make timely payments under the Convertible Note and failure
to timely comply with the reporting requirements of the Exchange Act. The Purchase Agreement and Convertible Note also contain affirmative
and negative covenants, including limitations on incurring additional indebtedness, the creation of additional liens on our assets, and
entering into investments, as well as a minimum liquidity requirement (for any date prior to the later of May 1, 2025 and the date of
the Authorized Share Increase (as defined in the Purchase Agreement), $30 million and thereafter, as of any date, the greater of (i)
$30 million less the sum of (1) twenty five percent (25%) of the unrestricted net cash proceeds received by us from Equity Issuances
(as defined in the Convertible Note) consummated since the issue date of the Convertible Note, which proceeds shall be available to be
used for general corporate and working capital purposes and shall not be subject to any clawbacks or other repayment covenants or obligations
or held in a blocked account or otherwise subject to any restrictions in use, plus (2) fifty percent (50%) of the aggregate Principal
Amount converted into Common Stock) and a cash burn requirement (on the last calendar date of each calendar month beginning with the
calendar month ended October 31, 2024, each, a Cash Burn Measurement Date, our Available Cash (as defined in the Convertible Note) on
the Cash Burn Measurement Date shall be greater than or equal to (i) our cash and cash equivalents on the Cash Burn Reference Date (as
defined in the Convertible Note), less (ii) $20 million).
Pursuant
to the Purchase Agreement, we agreed to prepare and file with the SEC this registration statement covering the resale of the Shares within
the timeframe set forth in the Purchase Agreement, and to use commercially reasonable efforts to cause this registration statement to
be declared effective within the timeframe set forth in the Purchase Agreement. Additionally, we agreed to prepare and file a proxy statement
with the SEC to seek stockholder approval at our next annual meeting of stockholders (and in any event prior to June 30, 2025) to amend
our certificate of incorporation to increase our authorized common stock by an additional 75,000,000 shares.
The
Offering
This
prospectus relates to the resale by the Selling Stockholder of up to 42,692,019 shares of our common stock issuable upon exercise
of the Convertible Note.
Shares
of common stock offered by the Selling Stockholder: |
|
Up
to 42,692,019. |
| |
|
|
Common
stock outstanding after this offering: |
|
259,619,994,
assuming that all Shares being offered pursuant
to this prospectus are actually issued upon conversion of the Convertible Note. |
| |
|
|
| Use
of proceeds: |
|
We
will not receive any proceeds from the sale of the Shares by the Selling Stockholder. |
| |
|
|
| Risk
factors: |
|
Investing
in our common stock involves a high degree of risk. See “Risk Factors” and other information contained in this
prospectus and incorporated by reference before deciding to invest in shares of our common stock. |
| |
|
|
Listing: |
|
Our
common stock is listed on The Nasdaq Global Market under the symbol “MVIS”. |
The
number of shares of our common stock to be outstanding after this offering is based on 219,018,180 shares outstanding as of November
4, 2024 and excludes, as of that date, the following:
| ● | 666,058 shares
of common stock issuable upon the exercise of outstanding options, of which 666,058
were exercisable at a weighted average exercise price of $1.43 per share under
our 2022 Incentive Plan, as amended, or the Incentive Plan; |
| ● | 12,655,588
shares
of common stock underlying unvested and/or deferred stock awards; and |
| ● | 2,822,270
shares
of our common stock reserved for issuance pursuant to the Incentive Plan. |
RISK
FACTORS
You
should carefully consider the specific risks set forth under the caption “Risk Factors” in our most recent annual report
on Form 10-K and quarterly report on Form 10-Q, each as amended or supplemented, which are incorporated by reference in this prospectus,
as the same may be amended, supplemented or superseded by our subsequent quarterly or annual reports or other filings, including filings
after the date hereof, with the SEC under the Exchange Act. The risks and uncertainties we describe are not the only ones facing us.
Additional risks not presently known to us or that we currently deem immaterial may also impair our business operations. If any of these
risks were to occur, our business, financial condition or results of operations would likely suffer. In that event, the trading price
of our common stock could decline, and you could lose all or part of your investment.
Risks
Related to Our Common Stock and this Offering
Our
stock price has fluctuated in the past, has recently been volatile and may be volatile in the future, and as a result, investors in our
common stock could incur substantial losses.
Our
stock price has fluctuated in the past, has recently been volatile and may be volatile in the future. During the 12 months prior to the
date of this prospectus, our common stock has traded at a low of $0.83 and a high of $2.78. We may continue to experience sustained depression
or substantial volatility in our stock price in the foreseeable future unrelated to our operating performance or prospects. For the year
ended December 31, 2023, we incurred a loss per share of $0.45.
| ● | As
a result of this volatility, investors may experience losses on their investment in our common
stock. The market price for our common stock may be influenced by many factors, including
the following: |
| ● | investor
reaction to our business strategy; |
| ● | the
success of competitive products or technologies; |
| ● | strategic
alternatives; |
| ● | the
timing and results of our development efforts with respect to our lidar sensors and ADAS
solutions; |
| ● | changes
in regulatory or industry standards applicable to our technologies; |
| ● | variations
in our or our competitors’ financial and operating results; |
| ● | developments
concerning our collaborations or partners; |
| ● | developments
or disputes with any third parties that supply, manufacture, sell or market any of our products; |
| ● | developments
or disputes concerning patents or other proprietary rights, including patents, litigation
matters and our ability to obtain patent protection for our products; |
| ● | actual
or perceived defects in any of our products, if commercialized, and any related product liability
claims; |
| ● | our
ability or inability to raise additional capital and the terms on which we raise it; |
| ● | declines
in the market prices of stocks generally; |
| ● | trading
volume of our common stock; |
| ● | sales
of our common stock by us or our stockholders; |
| ● | general
economic, industry and market conditions; and |
| ● | other
events or factors, including war, terrorism and other international conflicts, public health
issues including health epidemics or pandemics, such as the COVID-19 outbreak, and natural
disasters such as fire, hurricanes, earthquakes, tornados or other adverse weather and climate
conditions, whether occurring in the United States or elsewhere. |
Since
the stock price of our common stock has fluctuated in the past, has been recently volatile and may be volatile in the future, investors
in our common stock could incur substantial losses. In the past, following periods of volatility in the market, securities class-action
litigation has often been instituted against companies. Such litigation, if instituted against us, could result in substantial costs
and diversion of management’s attention and resources, which could materially and adversely affect our business, financial condition,
results of operations and growth prospects. There can be no guarantee that our stock price will remain at current levels or that future
sales of our common stock will not be at prices lower than those sold to investors.
Additionally,
securities of certain companies have recently experienced significant and extreme volatility in stock price due to short sellers of shares
of common stock, known as a “short squeeze.” These short squeezes have caused extreme volatility in both the stock prices
of those companies and in the market, and have led to the price per share of those companies to trade at a significantly inflated rate
that is disconnected from the underlying value of the company. Many investors who have purchased shares in those companies at an inflated
rate face the risk of losing a significant portion of their original investment, as in many cases the price per share has declined steadily
as interest in those stocks have abated. While we have no reason to believe our shares would be the target of a short squeeze, there
can be no assurance that we will not be in the future, and you may lose a significant portion or all of your investment if you purchase
our shares at a rate that is significantly disconnected from our underlying value.
You
will experience further dilution if we issue additional securities in future fundraising transactions.
We
are generally not restricted from issuing additional common stock, including any securities that are convertible into or exchangeable
for, or that represent the right to receive, common stock. If we issue additional common stock, or securities convertible into or exchangeable
or exercisable for common stock (including the additional $30,000,000 aggregate principal amount of senior secured convertible
notes which we could issue to the Selling Stockholder pursuant to the Purchase Agreement), our stockholders, including investors
who purchase shares of common stock in this offering, could experience additional dilution, and any such issuances may result in downward
pressure on the price of our common stock.
Sales
of shares of our common stock by the Selling Stockholder may cause our stock price to decline.
As
of November 4, 2024, we had 219,018,180 shares of common stock outstanding. Sales of substantial amounts of our shares
of common stock in the public market by the Selling Stockholder, or the perception that those sales may occur, could cause the market
price of shares of our common stock to decline and impair our ability to raise capital through the sale of additional shares of our common
stock.
We
do not currently intend to pay dividends on our common stock, and any return to investors is expected to come, if at all, only from potential
increases in the price of our common stock.
At
the present time, we intend to use available funds to finance our operations. Accordingly, while payment of dividends rests within the
discretion of our board of directors, no cash dividends on our common shares have been declared or paid by us and we have no intention
of paying any such dividends in the foreseeable future. Any return to investors is expected to come, if at all, only from potential increases
in the price of our common stock.
Risks
Related to the Convertible Note
There
are risks associated with our outstanding Convertible Note, and any additional convertible notes issuable under the Purchase Agreement,
that could adversely affect our business and financial condition.
As
of November 15, 2024, we had $45,000,000 of outstanding indebtedness under the Convertible Note. Pursuant to the Purchase Argument,
we can incur up to an aggregate of $75,000,000 million by issuing additional senior secured convertible notes to the Selling Stockholder
(up to an additional $30,000,000 additional aggregate principal amount), subject to certain limitations. The terms of any additional
senior secured convertible notes issued under the Purchase Agreement would be similar to those under the Convertible Note.
The
Convertible Note provides for certain events of default, such as our failing to make timely payments under the Convertible Note and failing
to timely comply with the reporting requirements of the Exchange Act. The Purchase Agreement and the Convertible Note also contain customary
affirmative and negative covenants, including limitations on incurring additional indebtedness, the creation of additional liens on our
assets, and entering into investments, as well as a minimum liquidity requirement described in “Summary—Convertible Note”
above.
Our
ability to remain in compliance with the covenants under the Convertible Note depends on, among other things, our operating performance,
competitive developments, financial market conditions and stock exchange listing of our common stock, all of which are significantly
affected by financial, business, economic and other factors. We are not able to control many of these factors. Accordingly, our cash
flow may not be sufficient to allow us to pay principal on the Convertible Note and any additional convertible notes issued under the
Purchase Agreement or meet our other obligations under the Purchase Agreement. Our level of indebtedness under the Purchase Agreement
could have other important consequences, including the following:
| ● | We
may need to use a substantial portion of our cash flow from operations to pay principal on
the Convertible Note and any additional convertible notes issued under the Purchase Agreement,
which would reduce funds available to us for other purposes such as working capital, capital
expenditures, potential acquisitions and other general corporate purposes; |
| ● | We
may be unable to refinance our indebtedness under the Purchase Agreement or to obtain additional
financing for working capital, capital expenditures, acquisitions, or general corporate purposes; |
| ● | We
may be unable to comply with financial and other covenants in the Convertible Note, which
could result in an event of default that, if not cured or waived, may result in acceleration
of the Convertible Note and any additional convertible notes issued under the Purchase Agreement
and would have an adverse effect on our business and prospects, could cause us to lose the
rights to our intellectual property, and could force us into bankruptcy or liquidation; |
| ● | The
conversion of the Convertible Note and any additional convertible notes issued under the
Purchase Agreement could result in significant dilution of our common stock, which could
result in significant dilution to our existing stockholders and cause the market price of
our common stock to decline; and |
| ● | We
may be more vulnerable to an economic downturn or recession and adverse developments in our
business. |
There
can be no assurance that we will be able to manage any of these risks successfully.
Our
obligations to the Selling Stockholder under the Convertible Note, and any additional senior secured convertible notes, are secured
by a security interest in all of our bank and securities accounts, now owned and hereafter created or acquired, and if we default on
those obligations, the Selling Stockholder could foreclose on our bank and securities accounts.
Our
obligations under the Convertible Note, and any additional senior secured convertible notes, and the related transaction documents,
are secured by a security interest in all of our bank and securities accounts, now owned and hereafter created or acquired. As a result,
if we default on our obligations under the Convertible Note, or additional senior secured convertible notes, the collateral agent
on behalf of the Selling Stockholder could foreclose on the security interests and liquidate some or all of our bank and securities accounts,
which would harm our business, financial condition and results of operations and could require us to reduce or cease operations and investors
may lose all or part of your investment.
USE
OF PROCEEDS
We
are registering the Shares on behalf of the Selling Stockholder, to be offered and sold by the Selling Stockholder from time to time,
and we will not receive proceeds from the sale of the Shares from time to time by the Selling Stockholder.
We
have agreed to pay all costs, expenses and fees relating to the registration of the Shares covered by this prospectus. These may include,
without limitation, all registration and filing fees, and fees and expenses of our counsel and accountants. The Selling Stockholder will
pay any underwriting discounts and expenses incurred for brokerage, accounting, tax or legal services or any other expenses incurred
in disposing of the Shares covered hereby.
DESCRIPTION
OF CAPITAL STOCK
Our
Amended and Restated Certificate of Incorporation, as amended, authorizes us to issue 310,000,000 shares of common stock, $0.001 par
value per share, and 25,000,000 shares of preferred stock, $0.001 par value per share. As of November 4, 2024, there were 219,018,180
shares of common stock, and no shares of preferred stock, outstanding.
Common
Stock. All outstanding common stock is, and any stock issued under this prospectus will be, duly authorized, fully paid and nonassessable.
Subject to the rights of the holders of our outstanding preferred stock, holders of common stock:
| |
● |
are
entitled to any dividends validly declared; |
| |
● |
will
share ratably in our net assets in the event of a liquidation; and |
| |
● |
are
entitled to one vote per share. |
The
common stock has no conversion rights. Holders of common stock have no preemption, subscription, redemption, or call rights related to
those shares.
Equiniti
Trust Company, LLC is the transfer agent and registrar for our common stock.
Preferred
Stock. The Board of Directors has the authority, without further action by the shareholders, to issue shares of preferred stock in
one or more series and to fix the rights, preferences, privileges and restrictions thereof, including dividend rights, conversion rights,
voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting any series or the
designation of such series. The issuance of preferred stock could adversely affect the voting power of holders of our common stock and
the likelihood that such holders will receive dividend payments and payments upon liquidation may have the effect of delaying, deferring
or preventing a change in control of MicroVision, which could depress the market price of our common stock. If we offer preferred stock,
the terms of that series of preferred stock will be set forth in the prospectus supplement relating to that series.
SELLING
STOCKHOLDER
The
shares of Common Stock that may be offered and sold by the Selling Stockholder are those issuable to the Selling Stockholder upon conversion
of the Convertible Note. For additional information regarding the issuance of the Convertible Note, see “Summary—Convertible
Note” above. We are registering the resale of such Shares in order to provide the Selling Stockholder with freely tradable securities.
Based
upon information provided by the Selling Securityholder, none of the Selling Stockholder nor any of its affiliates, officers, directors
or principal equity holders has held any position or office or has had any material relationship with us within the past three years.
Pursuant
to the terms of the Convertible Note, the Convertible Note may not be converted into shares of common stock if such conversion would
result in the Selling Stockholder owning an aggregate of in excess of 4.99% of the then-outstanding shares of common stock, provided
that such ownership limitation may be (i) increased by the Selling Stockholder to no greater than 9.99% upon 61 days’
notice and (ii) decreased immediately by the Selling Stockholder upon notice (such limitation the “Beneficial
Ownership Limitation”). The Selling Stockholder may sell all, some or none of its shares in this offering. See “Plan of Distribution.”
The
table below lists the Selling Stockholder and other information regarding the beneficial ownership (as determined under Section 13(d)
of the Exchange Act, and the rules and regulations thereunder) of the Shares held by the Selling Stockholder. The second column lists
the number of shares of common Stock beneficially owned by the Selling Stockholder, as of November 4, 2024, after giving effect
to the Beneficial Ownership Limitation. The percentages of common stock beneficially owned and being offered are based on 219,018,180
shares of our common stock outstanding as of November 4, 2024. The table below assumes that no Subsequent Closings (as defined
in the Purchase Agreement) have occurred.
The
fourth column lists the Shares that are being registered by this prospectus by the Selling Stockholder, without regard to the Beneficial
Ownership Limitation.
We
cannot advise you as to whether the Selling Stockholder will in fact convert the Convertible Note or sell any or all Shares issued pursuant
to such conversion. The fifth and sixth columns assume the sale of all of the Shares offered by the Selling Stockholder pursuant to this
prospectus, without regard to the Beneficial Ownership Limitation.
| | |
Number of Shares
of Common
Stock
Beneficially
Owned Prior
to
the Offering | | |
Maximum Number of Shares of Common Stock to be Sold Pursuant to this Prospectus | | |
Number of Shares
of Common
Stock
Beneficially
Owned After
the Offering | |
| Selling Stockholder | |
Number | | |
% | | |
Number | | |
Number | | |
% | |
| | |
| | | |
| | | |
| | | |
| | | |
| | |
| High Trail Special Situations
LLC(1) | |
| 10,929,008 | | |
| 4.99 | | |
| 42,692,019 | | |
| - | | |
| * | |
*
Less than 1%
| (1) |
Consists
of Shares issuable pursuant to the conversion of the Convertible Note, with the conversion thereof subject to the ownership limitations
described therein. Hudson Bay Capital Management LP, the investment manager of High Trail Special Situations LLC, has voting
and investment power over these securities. Sander Gerber is the managing member of Hudson Bay Capital GP LLC, which is the general partner
of Hudson Bay Capital Management LP. Each of High Trail Special Situations LLC and Sander Gerber disclaims beneficial ownership over
these securities. The address of the Selling Stockholder is c/o Hudson Bay Capital Management LP, 28 Havemeyer Place, 2nd Place, Greenwich,
CT 06830. |
PLAN
OF DISTRIBUTION
We
are registering the Shares to permit the resale of the Shares by the Selling Stockholder from time to time after the date of this prospectus.
We will not receive any of the proceeds from the sale of the Shares by the Selling Stockholder. We will bear all fees and expenses incident
to our obligation to register the Shares.
The
Selling Stockholder, which, as used herein, includes its respective pledgees, assignees, donees, transferees and successors-in-interest,
may, from time to time, sell any or all of the Shares covered hereby on the Nasdaq Global Market or any other stock exchange, market
or trading facility on which the Shares are traded or in private transactions. These sales may be at market prices prevailing at the
time of sale, at prices related to such prevailing market prices, at fixed prices or negotiated prices. The Selling Stockholder may use
any one or more of the following methods when selling the Shares:
| |
● |
ordinary
brokerage transactions and transactions in which the broker-dealer solicits purchasers; |
| |
● |
block
trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block
as principal to facilitate the transaction; |
| |
● |
purchases
by a broker-dealer as principal and resale by the broker-dealer for its account; |
| |
● |
an
exchange distribution in accordance with the rules of the applicable exchange; |
| |
● |
privately
negotiated transactions; |
| |
● |
settlement
of short sales; |
| |
● |
in
transactions through broker-dealers that agree with the Selling Stockholder to sell a specified number of such securities at a stipulated
price per security; |
| |
● |
through
the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise; |
| |
● |
a
combination of any such methods of sale; or |
| |
● |
any
other method permitted pursuant to applicable law. |
The
Selling Stockholder may also sell securities under Rule 144 or any other exemption from registration under the Securities Act, if available,
rather than under this prospectus.
There
can be no assurance that the Selling Stockholder will sell all or any of the Shares.
Broker-dealers
engaged by the Selling Stockholder may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions
or discounts from the Selling Stockholder (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser)
in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction not in
excess of a customary brokerage commission in compliance with FINRA Rule 2121, and in the case of a principal transaction a markup or
markdown in compliance with FINRA Rule 2121.
In
connection with the sale of the Shares or interests therein, the Selling Stockholder may enter into hedging transactions with broker-dealers
or other financial institutions, which may in turn engage in short sales of the Shares in the course of hedging the positions they assume.
The Selling Stockholder may also sell securities short and deliver these Shares to close out their short positions, or loan or pledge
the securities to broker-dealers that in turn may sell these Shares. The Selling Stockholder may also enter into option or other transactions
with broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer
or other financial institution of the Shares, which Shares such broker-dealer or other financial institution may resell pursuant to this
prospectus (as supplemented or amended to reflect such transaction).
Any
broker-dealers or agents that are involved in selling the Shares may be deemed to be “underwriters” within the meaning of
the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit
on the resale of the Shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act.
We
are required to pay certain fees and expenses incurred by us incident to the registration of the Shares. We have agreed to indemnify
the Selling Stockholder against certain losses, claims, damages and liabilities, including liabilities under the Securities Act. We agreed
to keep this prospectus effective until all of the Shares have been sold pursuant to this prospectus or Rule 144 under the Securities
Act or any other rule of similar effect or the Shares are otherwise freely tradeable under Rule 144. The Shares will be sold only through
registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the Shares
may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration
or qualification requirement is available and is complied with.
Under
applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the Shares may not simultaneously
engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M,
prior to the commencement of the distribution. In addition, the Selling Stockholder will be subject to applicable provisions of the Exchange
Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the common
stock by the Selling Stockholder or any other person.
WHERE
YOU CAN FIND MORE INFORMATION
We
file annual, quarterly and special reports, proxy statements and other information with the SEC. These documents are on file with the
SEC. Our SEC filings are also available to the public from the SEC’s website at www.sec.gov.
INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE
The
SEC allows us to “incorporate by reference” the information we file with them, which means that we can disclose important
information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus,
and the information that we file later with the SEC will automatically update and supersede this information. We incorporate by reference
the documents listed below and any future filings we will make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange
Act prior to the time that all securities covered by this prospectus have been sold; provided, however, that we are not incorporating
any information furnished under any of Item 2.02 or Item 7.01 (including exhibits furnished under Item 9.01 in connection with information
furnished under Item 2.02 or Item 7.01) of any current report on Form 8-K:
| |
● |
Our
Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC on February 29, 2024; |
| |
● |
Our
Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 29, 2024 (to the extent incorporated by reference into Part
III of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023); |
| |
● |
Our
Quarterly Reports on Form 10-Q for the quarters ended March
31, 2024, June
30, 2024 and September
30, 2024 filed with the SEC on May
10, 2024, August
8, 2024 and November
7, 2024, respectively; |
| |
● |
Our
Current Reports on Form 8-K filed with the SEC on February
3, 2023, as amended on April
18, 2023, on March
5, 2024, April
8, 2024, June
10, 2024, July
25, 2024, September
27, 2024, October 15, 2024 and October
15, 2024; and |
| |
● |
The
description of our Common Stock contained in Exhibit 4.2 to our Form 10-K for the fiscal year ended December 31, 2020, filed with
the SEC on March 15, 2021, including any amendments or reports filed for the purpose of updating this description. |
You
may request a copy of these filings, at no cost, by writing or telephoning us at the following address:
MicroVision,
Inc.
18390
NE 68th Street
Redmond,
Washington 98052
Attention:
Investor Relations
(425)
936-6847
You
can also find these filings on our website at www.microvision.com. We are not incorporating the information on our website other than
these filings into this prospectus.
This
prospectus is part of a registration statement that we have filed with the SEC. You should rely only on the information or representations
provided in this prospectus. We have not authorized anyone to provide you with different information. We are not making an offer of these
securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as
of any date other than the date on the front of the document.
LEGAL
MATTERS
For
the purpose of this offering, Ropes & Gray LLP is giving its opinion on the validity of the securities offered hereby.
EXPERTS
The
consolidated financial statements and financial
statement schedule of the Company as of December 31, 2023 and 2022 and for each of the three-years in the period ended December
31, 2023 incorporated in this prospectus by reference from the Annual Report on Form 10-K of the Company for the year ended December
31, 2023 and the effectiveness of our internal control over financial reporting, have been audited by Moss Adams LLP, an independent
registered public accounting firm, as stated in their report. Such consolidated financial statements and financial statement
schedule are incorporated by reference in reliance upon the report of such firm given their authority as experts in accounting and
auditing.
The
financial statements of Ibeo Automotive Systems GmbH appearing in our Current Report on Form 8-K/A Amendment No. 1 and filed with
the Securities and Exchanges Commission on April 18, 2023, have been audited by EY GmbH & Co. KG Wirtschaftsprüfungsgesellschaft
(formerly Ernst & Young GmbH Wirtschaftsprüfungsgesellschaft), an independent auditor, as set forth in their report
thereon, included therein and incorporated herein by reference. Such financial statements are incorporated herein by
reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing.
Microvision (NASDAQ:MVIS)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
Microvision (NASDAQ:MVIS)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024
